Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Clinical trial NCT01584531 · COMPLETED

Trial details

NCT number: NCT01584531
Sponsor: Traws Pharma, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Myelodysplastic Syndrome MDS Trisomy 8

Start date: 2012-05-01
Primary completion: 2015-05-01
Enrollment: 82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.